Studies have demonstrated that concentrations of methylated cfDNA at RASSF1A correlate with the response to neoadjuvant therapy in patients with breast cancer: patients with a decline in methylated RASSF1A cfDNA compared with pre-treatment often responded to neoadjuvant therapy [130]. The gene discussed is RASSF1; the disease is breast cancer.